Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Will The Necrotizing Enterocolitis Market Valuation Change Between Now And 2029?

The market for necrotizing enterocolitis has seen significant expansion in recent times. The market value is projected to rise from $4.83 billion in 2024 to $5.14 billion in 2025, leveraging a compound annual growth rate (CAGR) of 6.5%. The past growth is due to factors such as the increasing incidence of necrotizing enterocolitis, growing populations, rising per capita income, greater government funding, and a surge in premature birth cases.

In the coming years, the market size for necrotizing enterocolitis is projected to experience robust growth. It is forecasted to grow to $6.56 billion by 2029, expanding at a compound annual growth rate (CAGR) of 6.3%. This projected growth during the forecast period can be linked to factors such as escalating healthcare costs, the occurrence and prevalence of ulcerative colitis (UC), the surge in gastrointestinal diseases, the rising number of elderly and overweight individuals, and the burgeoning geriatric population. Some notable trends anticipated during the forecast period include advancements in biomarker research for early NEC detection, progress in non-invasive testing techniques, the adoption of cutting-edge monitoring systems, enhancements in surgical procedures, and the development of targeted treatment modalities.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22068&type=smp

What Underlying Factors Are Supporting The Necrotizing Enterocolitis Market Growth?

The surge in the number of premature births is anticipated to drive the growth of the necrotizing enterocolitis market in the future. Preterm births, also known as premature births, are when a baby is delivered prior to 37 weeks of pregnancy, as opposed to the standard full-term pregnancy of 40 weeks. The escalation in the incidence of premature births can be traced back to maternal health disorders such as hypertension, diabetes, and infections, which enhance the possibility of premature labor. Moreover, lifestyle factors like smoking, drug consumption, and inadequate nutrition also heighten the chances of preterm births. The rise in premature births subsequently ups the numbers of necrotizing enterocolitis (NEC) cases since newborns with underdeveloped gastrointestinal systems are more vulnerable to inflammation and infections. For example, according to the Centers for Disease Control and Prevention, a government agency in the US, premature births make up 8.67% of all births every year in the United States, as of January 2024. As such, the rise in premature births is accelerating the expansion of the necrotizing enterocolitis market.

Which Sub-Segments Are Driving Growth Within The Necrotizing Enterocolitis Market?

The necrotizing enterocolitismarket covered in this report is segmented –

1) By Treatment: Total Parenteral Nutrition (TPN); Gastrointestinal Decompression; Antimicrobial Therapy; Antifungal Treatment; Paracentesis; Other Treatments

2) By Diagnosis: Laboratory Tests; Imaging Techniques

3) By Stage: Stage I (Suspected Necrotizing Enterocolitis); Stage II (Definite Necrotizing Enterocolitis); Stage III (Advanced Necrotizing Enterocolitis)

4) By Distribution Channel: Direct Tender; Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels

5) By End-User: Hospitals; Neonatal Intensive Care Units (NICUs); Specialty Clinics

Subsegments:

1) By Total Parenteral Nutrition (TPN): Standard TPN Formulations; Customized Or Individualized TPN Solutions; Lipid Emulsions for TPN; Protein And Amino Acid Supplements In TPN; Micronutrient And Electrolyte-Enhanced TPN

2) By Gastrointestinal Decompression: Nasogastric Tube (NG Tube) Decompression; Orogastric Tube Decompression; Surgical Gastrostomy for Decompression; Non-Surgical Decompression Techniques

3) By Antimicrobial Therapy: Broad-Spectrum Antibiotics; Gram-Positive Coverage Antibiotics; Gram-Negative Coverage Antibiotics; Combination Antibiotic Therapy; Prophylactic Antibiotic Strategies For High-Risk Neonates

4) By Antifungal Treatment: Systemic Antifungal Therapy; Prophylactic Antifungal Therapy For Preterm Infants; Combination Antifungal And Antibiotic Therapy For Severe NEC

5) By Paracentesis: Diagnostic Paracentesis; Therapeutic Paracentesis; Guided Paracentesis using Ultrasound Or Radiological Techniques

6) By Other Treatments: Probiotics And Prebiotics for NEC Prevention; Surgical Interventions; Stem Cell Therapy And Regenerative Medicine Approaches; Immunomodulatory Therapies; Supportive Care

What Key Trends Are Driving Growth In The Necrotizing Enterocolitis Market?

Key companies in the necrotizing enterocolitis market are concentrating on developing innovative product solutions like cell-free sterile biologic solutions to meet the urgent need for effective therapies and improve outcomes in premature infants. A cell-free sterile biologic solution is a purified, sterile liquid that contains bioactive molecules—such as proteins, growth factors, and cytokines—sourced from cultured cells but without any living cells, aimed at promoting healing and reducing inflammation. For example, in December 2023, Noveome Biotherapeutics, Inc., a US biopharmaceutical firm, received clearance from the U.S. Food and Drug Administration (FDA) to initiate its Phase 1-2 clinical trial for ST266, an innovative biologic designed to treat necrotizing enterocolitis (NEC) in premature infants. This represents a crucial breakthrough, as ST266 is expected to be the first significant therapeutic advancement for NEC in more than three decades, addressing a pressing medical need given the high rates of morbidity and mortality in this vulnerable patient group.

Which Companies Hold A Competitive Edge In The 1571 Market?

Major companies operating in the necrotizing enterocolitis market are Abbott Laboratories, Astellas Pharma Inc., Mayo Foundation for Medical Education and Research, Cleveland Clinic, Boston Children’s Hospital, Hollister Incorporated, UPMC Children’s Hospital of Pittsburgh, Prolacta Bioscience Inc., Evolve BioSystems, Sigma-Tau Pharmaceuticals, Mead Johnson & Company LLC, Liminal BioSciences Inc., Noveome Biotherapeutics Inc., Infant Bacterial Therapeutics, Prometic Life Sciences Inc., Nexilico, Siolta Therapeutics, ProThera Biologics Inc., Plakous Therapeutics Inc., Chosen Diagnostics Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/necrotizing-enterocolitis-global-market-report

Which Region Dominates The Necrotizing Enterocolitis Market Today?

North America was the largest region in the necrotizing enterocolitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the necrotizing enterocolitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=22068&type=smp

Browse Through More Reports Similar to the Global Necrotizing Enterocolitis Market 2025, By The Business Research Company

Gastrointestinal Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-devices-global-market-report

Gastrointestinal Bleeding Treatment Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-bleeding-treatment-devices-global-market-report

Gastrointestinal Endoscopy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-endoscopy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model